Description: NeuroPharm Biologics develops precision phage therapies targeting antibiotic-resistant infections, showing 90% efficacy in clinical trials. Our engineered bacteriophages specifically target superbugs without affecting beneficial bacteria. Partnered with 18 teaching hospitals for clinical studies. The Boston BSL-4 lab produces customized phage treatments within 48 hours. Recently received FDA Breakthrough status for resistant staph infections. Training infectious disease specialists in phage application protocols.